Skip to main content
. 2023 Jan 5;50(5):1466–1486. doi: 10.1007/s00259-022-06089-w

Table 1.

Indications for PSMA-ligand PET/CT

Routine clinical use
 Initial staging of prostate cancer
 Localization of recurrent (BCR) or persistent (BCP) prostate cancer
 Localization of prostate cancer which is non-metastatic by conventional imaging (nmCRPC)
 Staging before PSMA-directed radioligand therapy
Potential clinical applications
 Guidance of prostate biopsy
 Imaging metastatic prostate cancer
 Monitoring of systemic treatment for metastatic prostate cancer